Targeted profiling of atherogenic phospholipids in human plasma and lipoproteins of hyperlipidemic patients using MALDI-QIT-TOF-MS/MS

Atherosclerosis

Volumn 224, Issue 1, 2012, Pages 177-186

  Stübiger, Gerald ^a   Aldover Macasaet, Elsie ^a   Bicker, Wolfgang ^b   Sobal, Grazyna ^a   Willfort Ehringer, Andrea ^a   Pock, Katharina ^c   Bochkov, Valery ^a   Widhalm, Kurt ^a   Belgacem, Omar ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b FTC Forensic Toxicological Laboratory Ltd   (Austria)

^c Octapharma Pharmazeutika Produktions GmbH   (Austria)

^d Shimadzu   (United Kingdom)

Author keywords

Atherosclerosis; Clinical lipidomics; Familial hyperlipidemia; LC ESI (SRM) MS MS; Lipid biomarkers; Lyso phosphatidylcholine (LPC); MALDI (QIT) TOF MS( MS); Oxidized phospholipids (OxPLs); Sphingomyelin (SM)

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; PHOSPHOLIPID;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSLIPIDEMIA; ELECTROSPRAY MASS SPECTROMETRY; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHENOTYPE; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL;

ADOLESCENT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHILD; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; LYSOPHOSPHATIDYLCHOLINES; MALE; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPHINGOMYELINS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84865400140     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.06.010     Document Type: Article

References (46)

1. Kannel W.B., Castelli W.P., Gordon T., McNamara P.M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971, 74:1-12.
2. Miller N.E., Miller G.J. Letter: high-density lipoprotein and atherosclerosis. Lancet 1975, 1:1033.
3. Tomkin G.H. Atherosclerosis, diabetes and lipoproteins. Expert Rev Cardiovasc Ther 2010, 8:1015-1029.
4. van der G.A., Kastelein J.J., Wiegman A. Heterozygous familial hypercholesterolaemia in childhood: cardiovascular risk prevention. J Inherit Metab Dis 2009, 32:699-705.
5. Berenson G.S., Srinivasan S.R., Bao W., Newman W.P., Tracy R.E., Wattigney W.A. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa heart study. N Engl J Med 1998, 338:1650-1656.
6. Widhalm K., Binder C.B., Kreissl A., et al. Sudden death in a 4-year-old boy: a near-complete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. J Pediatr 2011, 158:167.
7. Zalewski A., Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005, 25:923-931.
8. Quehenberger O., Dennis E.A. The human plasma lipidome. N Engl J Med 2011, 365:1812-1823.
9. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 1994, 344:793-795.
10. Napoli C., Postiglione A., Triggiani M., et al. Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia. Atherosclerosis 1995, 118:259-273.
11. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005, 353:46-57.
12. Tabas I. Nonoxidative modifications of lipoproteins in atherogenesis. Annu Rev Nutr 1999, 19:123-139.
13. Tsimikas S., Kiechl S., Willeit J., et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 2006, 47:2219-2228.
14. Matsumoto T., Kobayashi T., Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem. 2007, 14:3209-3220.
15. Schlitt A., Blankenberg S., Yan D., et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metabol (Lond) 2006, 3:5.
16. Han X., Gross R.W. Electrospray ionization mass spectroscopic analysis of human erythrocyte plasma membrane phospholipids. Proc Natl Acad Sci U S A 1994, 91:10635-10639.
17. Schiller J., Suss R., Arnhold J., et al. Matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) mass spectrometry in lipid and phospholipid research. Prog Lipid Res 2004, 43:449-488.
18. Zehethofer N., Pinto D.M. Recent developments in tandem mass spectrometry for lipidomic analysis. Anal Chim Acta 2008, 627:62-70.
19. Stubiger G., Belgacem O. Analysis of lipids using 2,4,6-trihydroxyacetophenone as a matrix for MALDI mass spectrometry. Anal Chem 2007, 79:3206-3213.
20. Stubiger G., Pittenauer E., Belgacem O., Rehulka P., Widhalm K., Allmaier G. Analysis of human plasma lipids and soybean lecithin by means of high-performance thin-layer chromatography and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 2009, 23:2711-2723.
21. Stubiger G., Belgacem O., Rehulka P., Bicker W., Binder B.R., Bochkov V. Analysis of oxidized phospholipids by MALDI mass spectrometry using 6-aza-2-thiothymine together with matrix additives and disposable target surfaces. Anal Chem 2010, 82:5502-5510.
22. Stubiger G., Sobal G., Widhalm K., Belgacem O., Pock K. Influence of HSA and IgG on LDL oxidation studied by size-exclusion chromatography and phospholipid profiling using MALDI tandem-mass spectrometry. Chem Phys Lipids 2011, 164:563-572.
23. Koy C., Mikkat S., Raptakis E., et al. Matrix-assisted laser desorption/ionization- quadrupole ion trap-time of flight mass spectrometry sequencing resolves structures of unidentified peptides obtained by in-gel tryptic digestion of haptoglobin derivatives from human plasma proteomes. Proteomics 2003, 3:851-858.
24. Labropoulos N., Zarge J., Mansour M.A., Kang S.S., Baker W.H. Compensatory arterial enlargement is a common pathobiologic response in early atherosclerosis. Am J Surg 1998, 176:140-143.
25. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
26. Zhao Z., Xu Y. An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples. J Lipid Res 2010, 51:652-659.
27. Belgacem O., Stubiger G., Allmaier G., Buchacher A., Pock K. Isolation of esterified fatty acids bound to serum albumin purified from human plasma and characterised by MALDI mass spectrometry. Biologicals 2007, 35:43-49.
28. Oskolkova O.V., Afonyushkin T., Preinerstorfer B., et al. Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. J Immunol 2010, 185:7706-7712.
29. Frey B., Haupt R., Alms S., et al. Increase in fragmented phosphatidylcholine in blood plasma by oxidative stress. J Lipid Res 2000, 41:1145-1153.
30. Podrez E.A., Byzova T.V., Febbraio M., et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007, 13:1086-1095.
31. Myher J.J., Kuksis A., Pind S. Molecular species of glycerophospholipids and sphingomyelins of human plasma: comparison to red blood cells. Lipids 1989, 24:408-418.
32. Wiesner P., Leidl K., Boettcher A., Schmitz G., Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009, 50:574-585.
33. Stubiger G., Sobal G., Montgomery H., Widhalm K., Pock K., Belgacem O. Novel approach for detection of dietary based changes of plasma lipids and molecular lipoprotein modifications. Atheroscler Suppl 2008, 9:157.
34. Le N.A., Walter M.F. The role of hypertriglyceridemia in atherosclerosis. Curr Atheroscler Rep 2007, 9:110-115.
35. Jeong T., Schissel S.L., Tabas I., Pownall H.J., Tall A.R., Jiang X. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 1998, 101:905-912.
36. Schissel S.L., Tweedie-Hardman J., Rapp J.H., Graham G., Williams K.J., Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996, 98:1455-1464.
37. Escriba P.V. Membrane-lipid therapy: a new approach in molecular medicine. Trends Mol Med 2006, 12:34-43.
38. Domingues M.R., Reis A., Domingues P. Mass spectrometry analysis of oxidized phospholipids. Chem Phys Lipids 2008, 156:1-12.
39. Kern H., Volk T., Knauer-Schiefer S., et al. Stimulation of monocytes and platelets by short-chain phosphatidylcholines with and without terminal carboxyl group. Biochim Biophys Acta 1998, 1394:33-42.
40. Boullier A., Gillotte K.L., Horkko S., et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 2000, 275:9163-9169.
41. Karakatsani A.I., Liapikos T.A., Troganis A.N., Tsoukatos D.C. Involvement of phospholipids in apolipoprotein B modification during low density lipoprotein oxidation. Lipids 1998, 33:1159-1162.
42. Horkko S., Bird D.A., Miller E., et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999, 103:117-128.
43. Edelstein C., Pfaffinger D., Hinman J., et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003, 278:52841-52847.
44. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561.
45. Bowry V.W., Stanley K.K., Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 1992, 89:10316-10320.
46. Proudfoot J.M., Barden A.E., Loke W.M., Croft K.D., Puddey I.B., Mori T.A. HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res 2009, 50:716-722.